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Autoimmune Connective Tissue 
Diseases 
incidence 
1. Systemic lupus erythematosus         15-50/100 000 
2. Scleroderma                                         <10/100 000 
3. Polymyositis                                          <10/100 000 
 4. Dermatomyositis                                  <10/100 000 
5. Rheumatoid arthritis                             <10/100 000 
6. Sjogren’s syndrome                                0.5 to 3.6% 
   
Relevance 
•  As many as 25% of connective tissue disease 
patients present with features of systemic lupus 
erythematosus, systemic sclerosis, polymyositis, or 
dermatomyositis, with rheumatoid arthritis and 
Sjögren's syndrome evolving concurrently or 
consecutively during the course of the disease  
• Frequently these circumstances make the diagnosis of 
a specific rheumatic disease difficult  
• It is still contentious whether or not overlap syndromes 
represent the coexistence of separate diseases, the 
broad clinical expression of the one rheumatic 
disease, or distinct clinical entities with distinctive 
aetiology and pathogenesis 
Definition 
• "Overlap syndromes" refers to a diverse 
group of conditions that have clinical 
features of, and meet classification criteria 
for, more than 1 well-characterized 
rheumatic disease  
• The pattern of organ involvement reflects 
the characteristic features of the well-
defined rheumatic diseases occurring 
together 
https://online.epocrates.com/diseases/101821/Overlap-syndromes/Definition 
Clinical classification 
• Mixed connective tissue disease = high titer of U1-
RNP autoantibodies + SLE + scleroderma + 
myositis + rheumatoid arthritis 
• Antisynthetase syndrome = aminoacyl-tRNA 
synthetase enzymes + myositis + arthritis + 
interstitial lung disease  
• Polymyositis/scleroderma syndrome = PM/Scl 
antibody + scleroderma + polymyositis, + Raynaud 
phenomenon + tendon inflammation + interstitial 
lung disease 
    ٭Experts are increasingly realizing that overlap 
syndromes of scleroderma and myositis are more 
common than the “pure” forms of the disease 
  Incidence and Prevalence  
• There are no epidemiology studies of 
overlap syndromes, apart from Japan, 
where the reported prevalence of mixed 
connective tissue disease (MCTD) is 2.7 
per 100,000 
• Antisynthetase antibodies (including anti-
Jo-1 or antihistidyl-tRNA) are found in 5% 
to 20% of patients with polymyositis or 
dermatomyositis 
Kelley's.Textbook.of.Rheumatology.9th.Ed 
Patient A 
71 yr old caucasian 
female 
MAIN 
• Dyspnoea during minor physical exertion ( up to 
50m of quite walking on ground level), no at rest 
• Dry cough 
• Intermittent wheezing, sensation of obstructed 
expiration during physical exertion, as well as at 
rest or at night 
• Chest tightness  
• Lower extremities edema in the evening, after 
night it abates 
Presenting Complaint 
ADDITIONAL 
• Mouth dryness, difficulty swallowing 
• Pain and sandy sensation in the eyes 
• Dryness of skin 
• Numbness and tingling of the lower limbs, 
especially distal parts, and the lateral aspects of 
the face  
• Muscle weakness, especially during raising the 
hands up 
• Intermittent joint pain in the knees, shoulders, 
wrist, ankles  
• Subfebrile fever (up to 37.4°C)  
• Fatigue 
• Photosensitivity 
Presenting Complaint 
History of Presenting Complaint  
Over 7 years (since 2011) patient suffers from dryness 
of eyes and mouth, intermittent pain in parotid salivary 
gland. 
She was surveyed and treated by rheumatologist about  
Sjögren Syndrome, moderate level of activity  
Symptomatic treatment: • life style modification 
                                        • artificial tears liberally 
During last year patient noticed numbness and tingling 
of the lower limbs and face, muscle weakness, rash 
on eyelids, fatigue, fever, photosensitivity 
Rheumatologist diagnosed dermatomyositis  
Manaement:       • glucocorticoids 12 mg daily  
                           • methotrexate 7.5 mg per week  
Recent month occurred worsening, developed severe 
progressive dyspnea, dry cough 
• Frequent flu 
• Appendicitis complicated by peritonitis in 
youth 
Past Medical History 
• Artificial tears liberally 
• Topical NSAIDs for joint pain 
 
Drug History 
Allergies and Reactions 
• No 
Social History 
• Retired 
• Worked as a programmer 
• Has a daughter 
• Live in a flat 
• No history of smoking 
• No history of alcohol 
• No history of illicit drug use 
Family History 
• Her mother suffered from musculoskeletal pain; 
she was not surveyed and had not precise 
diagnosis; she used NSAIDs and troxerutin gel 
locally to relieve her symptoms 
• Her brother suffered from skin disease with 
hyperkeratosis, presumably seborrhea 
• No family history  of hypertension,  diabetes 
mellitus   
VITAL SIGNS 
• T           37,1°C 
• PS         70 bpm 
• BP         140/80 mm Hg 
• RR         16 tpm 
• Height    160 cm 
• Weight    68 kg 
• BMI         27 
Elderly female is well oriented to space and time 
The posture is active,   
Central type of obesity (waist circumference 112 cm) 
Skin - is pale and dry 
        - face and neck erythema – V-sign 
        - eyes are puffy, periorbital violaceous erythema 
– heliotropic rash 
         - hand puffiness 
         - skin of the fingers is dry, rough, with a signs of 
hyperkeratosis and small fissures, no focal thickening 
were detected - Mechanic’s hand 
Examination 
Heliotropic Rash, V-sign 
Mechanic’s hand 
 
Conjunctiva is dry, hyperemic, but without fibrin 
threads and erosions/ulcers, yellowish crusts at 
the eyelids 
Dryness of mucous membranes of the mouth, 
single erosions 
Tongue is dry and bright pink, multiple fissures are 
present  
Parotid and submandibular salivary glands are 
tender to palpation 
Examination 
During lung percussion resonant sound is detected, 
borders are not changed 
Bronchial breathing in lungs to auscultation, on basal 
parts of both lung occur fine crackles 
Peripheral pulse is full and regular 
JVP + 2cm 
Apex beat is in 5th intercostal space 1 cm to the left of 
the left midclavicular line, has diminished force 
 Soft S1 and S2 heart sounds to auscultation, diffuse 
systolic murmur (grade II) at all points of auscultation 
Abdomen is increased in size, participate in breathing 
actively, old scar after median laparotomy is present; 
during palpation is soft and non tender, 
hyperpneumatosis occur, no visceromegaly 
Examination 
Joints during examination are not changed, passive 
and active movement is painless 
Peripheral muscles are atrophic, tender and dense 
to palpation, strength of shoulder girdle muscles 
is diminished, distal muscle strength is preserved 
Peripheral oedema is absent at the time of 
examination  
Stool is daily 
Urination is decreased (no more than 1000 ml/24h) 
Unstimulated  salivary flow during 15 minutes 
equals <1 mL  
Examination 
Preliminary Diagnosis 
Sjögren Syndrome  
Dermatomyositis?  
Overlap syndrome?  
Paraneoplastic syndrome? 
  
Workup 
• Complete blood count 
• Urine analisis 
• Biochemical blood profile 
• Infectious profile 
• Rheumatologic profile 
• Immunologic profile 
• Thyroid function tests 
• ECG 
• Pulmonary function tests 
• Chest CT-scan 
• Upper GIT endoscopy 
• Double-contrast barium enema examination (Irrigoscopy) 
• Echocardiography 
• Abdomen ultrasound 
• Thyroid ultrasound 
Complete Blood Count 
Results Reference range 
RBC  4.56×1012/L 3.7-4.7×1012/L 
Hb 141 g/L 120-140 g/L 
WBC  7.0×109/L 4.0-9.0×109/L 
Neutrophils 59% 47,0-72%  
Bands 3% 1-6% 
Eosinophils 1% 0,5-5,0%  
Basophils 0.2% 0,0-1,0%  
Lymphocytes 33% 19,0-37,0%  
Monocytes 4% 3,0-10,0%  
Thrombocytes  201×109/L 180-320×109/L 
Normal values 
Urine Analysis 
Results Reference range 
Colour  Light yellow  
Specific gravity  1.017 1.001-1.040 
pH   5.6 5.0-7.0 
Protein  -- -- 
Glucose -- -- 
Leucocytes 1-2/hpf 6-8/hpf 
Erithrocytes 2-4/hpf single 
Transitional epithelium  single single 
Casts  -- -- 
Crystals  -- -- 
Normal values 
Biochemical Blood Profile 
Results  Reference range 
Glucose (capillar) 4.53 mmol/L 3.3-5.5 mmol/L 
AlAT 83 U/L <33.0 U/L 
AsAT 45 U/L <32.0 U/L 
Bilirubin total 
              direct 
             indirect 
19.0 mkmol/L 
4.1 mkmol/L 
14.9 mkmol/L 
17-21 mkmol/L  
<5.0 mkmol/L  
AP  75  U/L 35-104 U/L 
LDH 296.53 U/L 135.0-214.0 U/L 
α-amylase (serum)  58.5 U/L 28.0-100.0 U/L 
Creatine kinase 261 U/L 26.0-140.0 U/L 
Creatinine 87 mkmol/L 53.0-97.2 mkmol/L 
Urea 3.0 mmol/L 2.76-8.07mmol/L 
Rise of transaminases AlAT, AsAT, LDH  and CK indicates 
presence of miositis 
Biochemical Blood Profile 
Results  Reference range 
Potassium 3.0 mmol/L 3.5-5.1mmol/L 
Sodium 145.3 mmol/L 136.0-145.0 mmol/L 
Chloride 82.3 mmol/L 98.0-107.0 mmol/L 
Phosphorus  0.82 mmol/L 0.81-1.45 mmol/L 
Calcium  2.13 mmol/L 2.2 -2.55 mmol/L 
Hypokaliemia 
Hypochloremia 
Hypocalcemia 
Biochemical Blood Profile 
• CA-19-9  29.0 U/mL 
 
 
 
 
Oncomarker to colonic, pancreatic, 
gallbladder cancers is negative  
 
Infectious Profile 
Results  Reference range 
HBsAg Negative  Negative  
HCV Negative  Negative  
Human herpes virus 6  
Ig G 
6,49 U 
positive 
< 0.9 – negative 
0.9-1.1 – suspicious   
1.1 – positive Human herpes virus 5  
Cytomegalovirus Ig M 
0.1  
negative 
Human herpes virus 5  
Cytomegalovirus Ig G 
11.4 U  
positive 
Human herpes virus 3 
Varicella Zoster Ig M 
<0.1  
Negative 
Human herpes virus 3 
Varicella Zoster Ig G 
6,49 U 
positive 
HTLV type1 Negative Negative 
HIV Negative Negative 
Chronic herpes virus infection 6, 5, 3 
Rheumatologic Profile 
Results  Reference range 
ESR 35 mm/h <30mm/h 
C-RP 3.6 mg/L < 5.0 mg/L 
RF 37.0 IU/mL < 14 IU/mL 
Sialic acids 1.9 mkmol/L 2.0-2.33 mkmol/L 
Seromucoids 4.5 U/L 0.13-0.2 U/L 
LE cells  Negative Negative 
ESR, RF may rise at various rheumatic and 
nonrheumatic pathologies 
Immunologic Profile 
Results  Reference range 
ANA 1:3200 < 1:100 – negative 
Anti-dsDNA, IgG  >300 AI  
 
 
 
 
 
<1.0 Negative 
 
≥1.0 Positive 
Nucleosome, Chromatin Ab, IgG 0.8 AI 
Аnti-Rib-P, Ig G  0.2 AI 
Anti-SS-A, IgG >8 AI 
Anti-SS-B IgG >8 AI 
Anti-SmI gG 0.7 AI 
Anti-Sm/RNP IgG 0.3 AI 
Anti-RNP IgG <0.2 AI 
Anti-Scl-70 IgG <0.2 AI 
Anti-JO-1 IgG >8 AI 
Anti-Centromere B, IgG  <0.2 AI 
Elevated ANA, anti-DNA antibodies present in variety 
autoimmune and rheumatic diseses 
High titers of SS-A IgG + SS-B IgG indicates presence of 
Sjögren’s syndrome  
Anti-JO-1 antibodies are associated with antisynthetase 
syndrome 
Immunologic Profile 
Results  Reference range 
MPO <0.2 AI  
<1.0 Negative 
≥1.0 Positive 
Serine Protease 3 Ab, IgG  <0.2 AI 
Anti-GMB, Ig G <0.2 AI 
There is no evidence of systemic vasculitis 
Thyroid Function Tests 
Results  Reference range 
TSH 13.38 μU/mL  0.27-4.2 μU/mL  
T4 free 0.88 ng/dL 0.93-1.7 ng/dL 
TPO 31.7 IU/mL <34 IU/mL 
Hypothyroidism 
ECG 
Low voltage ECG, sinus rhythm, 70 bpm, normal heart 
axis, ventricular premature contraction, right atrial 
enlargment (II,III), violation of repolarization in V5-V6 
Echocardiography 
• Aorta: moderate consolidation of the wall 
• Left and right atria are not enlarged 
• Left ventricle  
Norma Result 
LV EDD 46–57 mm 41.8 mm 
LV ESD 31–43 mm 22.1 mm 
LVPW 7–11 mm 12.2 mm 
VST 7-11mm 12.9 mm 
EF 55-78 % 78 % 
 SV 60-100ml 61.3 ml 
Increase total contractility of the left 
ventricle  
Increase diastolic stiffness of both 
ventricles 
• Right ventricle 
Aortic sclerosis                Signs of pulmonary hypertension 
LV and RV hypertrophy        Mild pericardial effusion 
Diastolic dyfunction 
Norma Result 
RV EDD 46–20.5 mm 22 mm 
RVW 31–43 mm 6 mm 
• Pericardial effusion, max thickness 7 mm in LV PW 
Moderate violation of lung ventilation, mixed (obstructive 
& restrictive) type, salbutamol test: +10% FEV1 
Pulmonary Function Tests 
Chest CT-Scan 
Moderate apical pneumofibrosis 
In the lower lobe of both lungs detected areas of decreased 
pneumatisation with indistinct borders – ground 
glass pattern, up to 45ˣ30 mmØ 
Haemostasis 
Reference range 
Prothrombin time 11.9 s 9.9-11.8 s 
INR 1.09 <1.0 
APTT 22.6 s 22.7-31.8 s 
Thrombin time 17.7 s 14.0-21.0 s 
Fibrinogen 3.141 g/L 1.8-3.5 g/L 
D-dimer 8.1 μFEU/mL <0.5 μFEU/mL 
Evidence of thrombosis 
CT Pulmonary Angiography 
• Signs of multiple segmental 
thromboembolism of the pulmonary artery 
branches (segmental arteries of 4,5,8,9 
segments of the left lung and 4,6,9,10 
segments of the right lung) 
Upper GIT Endoscopy 
 
• Esophagus is accessible to pass; mucosa is pink; III 
degree (total) lower esophageal sphincter opening 
• Stomach contain large amount of fluid with bile 
admixture; antrum is hyperemic and edematous 
• Pylorus and duodenum are not changed 
 
  
 
 
Lower esophageal sphincter failure, GERD 0 stage 
Duodenogastral reflux  
Erythematous reflux gastritis 
Double-Contrast Barium Enema 
Examination (Irrigoscopy) 
All parts of the colon are filled by contrast and air. 
There is no narrowing. Gaustration is 
pronounced in all parts, unremarkable. Emptying 
of the colon is delayed. Mucosa of the 
descending colon has thickened folds. Lesions 
are not determined.  
 
 
Descending colitis 
Organic changes of the colon are not 
determined 
Abdomen Ultrasound 
 
• Kidneys’ echogenicity is increased, single 
cysts (22, 26, 28, and 34 mm Ø) 
• Liver normal sized, echogenicity is 
increased 
• Galbladder, pancreas, spleen are not 
changed 
 
Diffuse pathology of the liver and 
kidneys, multiple kidneys’ cysts 
Thyroid Ultrasound 
 
• Thyroid gland is normal sized 
• In the left lobe visualized cyst 15×13mm, 
anechogenic growth 9×7mm 
• Thyroid isthmus anechogenic growth with colloid 
4-5mm 
 
 
 
Thyroid nodules 
Goiter I degree 
Consultations 
 Gastroenterologist 
 
Moderate GERD. Chronic refluxgastritis. 
Duodenogastral reflux.  
Consultations 
 Endocrinologist 
 
Autoimmune thyroiditis. Goiter I degree. 
Hypothyroidism. 
Consultations 
 Ophthalmologist  
 
Dry eye syndrome. Angiopathy of retina of 
both eyes 
 
 Pathology was not detected. Involutive 
changes of uterus. Inspection of mammal 
glands are unremarkable. 
 
Consultations 
Gynecologist 
Complementary Tests 
• Right-heart catheterization with 
documentation of vasomotor responsiveness 
to vasodilators  
• Electromyography 
• Muscle MRI  
• Skin and muscle biopsy 
• anti-TPO and anti-Tg antibodies 
• Glycemic profile 
• OGTT 
Autoantibodies related to overlap 
myositis syndrome and associated 
clinical characteristics 
http://emjreviews.com/wp-content/uploads/Idiopathic-Inflammatory-Myopathies-Association-with-Overlap-Myositis-and-Syndromes-Classification-Clinical-Characteristics-and-Associated-Autoantibodies.pdf 
AECG Diagnostic Criteria 
Sjögren’s syndrome 
The presence of four out of the six items, including positive history or 
serology, or the presence of three of the four objective items 
1. Ocular symptoms: positive response to one of the following questions:  
• have you had daily persistent trouble with dry eyes for more than 3 months? 
• do you have a recurrent sensation of sand or gravel in the eyes? 
• do you use tear substitutes more than three times per day? 
2. Oral symptoms: positive response to one of the following questions:  
• have you had a daily feeling of dry mouth for more than 3 months?  
• have you had recurrent or persistent swollen salivary glands as an adult?  
• do you frequently drink liquids to aid swallowing dry food? 
3. Ocular signs: positive Schirmer’s test performed without anesthesia (5 mm in 5 
minutes) or positive rose bengal score (≥4) 
4. Histopathology: focal lymphocytic sialadenitis with a focus score > one focus per 
4 mm2 of minor salivary glandular tissue 
5. Salivary gland involvement: a positive response for at least one of the following 
diagnostic testing:  
• unstimulated whole salivary flow (<1.5 mL in 15 minutes) or parotid sialography 
showing the presence of diffuse sialectasis 
• parotid gland sialography showing the presence of diffuse sialectasis without 
evidence of obstruction in the glands 
• salivary scintigraphy showing delayed uptake, reduced concentration, and/or 
delayed excretion of tracer 
6. Autoantibodies: presence of anti-SSA (Ro) or anti-SSB (La) or both 
Sjögren’s International Collaborative 
Clinical Alliances Cohort 
At least two out of the three objective 
criteria needed for the diagnosis  
1. Positive anti-SSA (Ro) and/or Anti-SSB 
(La) or positive RF and ANA ≥1:320 
2. Labial salivary gland biopsy with a focal 
lymphocytic sialadenitis with a focus 
score ≥ one focus per 4 mm² 
3. Keratoconjunctivitis sicca with an ocular 
staining score ≥3 
Final Diagnosis 
MAIN 
Primary Sjögren’s syndrome, moderate. 
Anti-Jo-1-antisynthetase syndrome.  Interstitial 
lung disease. Non-massive pulmonary 
thromboembolism. Pulmonary hypertension. 
Respiratory failure type I 
Chronic mild pericarditis associated with rheumatic 
disease. Heart failure with preserved EF (78%) II FC 
NYHA 
 
CONCOMITANT 
Autoimmune thyroiditis, hypothyroidism 
Moderate GERD. Chronic refluxgastritis. 
Duodenogastral reflux. Descending colitis. 
 
Management 
Pulmonary embolism 
• Enoxaparin 60 mg bid #7 
• Varfarin 5 mg controlled by INR 2-3 
Symptomatic treatment 
• Methylprednisolone 64 mg daily 
• Mycophenolate mofetil 60 mg daily with following 
titration 
• Omeprazole 20 mg in the morning 
Further treatment of pulmonary hypertension 
• Diltiazem-retard 90 mg bid 
• Sildenafil 5 mg tid 
Herpes virus infection 
• Acyclovir 400 bid 
Prognosis 
• Patients with antisynthetase syndrome are 
generally considered to have a poor prognosis, with 
mortality 3 times greater than that of myositis 
without antisynthetase syndrome 
• The overall outlook is defined by the severity of 
organ involvement.  
• The onset of pulmonary hypertension, cardiac 
involvement, or interstitial lung disease each 
portends a poorer prognosis, and they are 
indications for aggressive immunosuppressive 
therapy 
•  Pulmonary hypertension is the commonest 
disease-related cause of death in patients with 
antisynthetase syndrome  
Conclusion 
• Connective tissue diseases are 
characterised by considerable clinical 
diversity and heterogeneity 
• Characteristic clinical features and the 
detection of specific autoantibodies help to 
define these disorders and facilitate 
diagnosis and appropriate treatment 
 
Conclusion 
• It should be noted that overlap between 
organ specific autoimmune syndromes, 
such as myasthenia gravis, Hashimoto's 
thyroiditis, and insulin dependent diabetes 
mellitus, is frequently seen  
Conclusion 
• There are no FDA-approved therapies for the 
management of any of the overlap syndromes 
• There is a paucity of data from controlled trials to 
support management strategies, in whom the 
clinical features and need for treatment are 
highly variable and tailored to the organ systems 
involved and the severity of involvement 
•  The overall goal of therapy is symptom control 
and, where possible, arrest of the underlying 
autoimmune disease process  
Unresolved Questions 
• To determine the origin of chronic and 
persistent activation of immune system 
• To elucidate the role of immunologic, 
immunogenetic and neuroendocrine 
factors in the pathogenesis of the disease 
• To find a specific immune intervention to 
alleviate disease 
